Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study

NCT ID: NCT02082613

Last Updated: 2016-04-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare a minimal invasive operation in local anesthesia with sclerotherapy for symptomatic testicular hydrocele within 6 months after randomization. Thirty days complication rates will be assessed. The hypothesis is that surgery will lead to faster cure while sclerotherapy would be cheaper and have less complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Testicular hydrocele is a common disorder even though it´s exact prevalence is unknown. In areas with filariasis it´s endemic.

Hydrocele is a benign condition where fluid accumulates in between two layers of tunica vaginalis (embryologically, the peritoneum), surrounding the testicle. The cause is unknown but inflammatory conditions is believed to induce these changes. The pathogenesis of hydrocele is believed to be a nonbalanced secretion and resorption of fluid.

Diagnosis of hydrocele is easy since the patient presents with an enlarged scrotum and clinical investigation including palpation and transillumination of the scrotum confirms the diagnosis. A scrotal ultrasound might be indicated to rule out a malignancy or if the diagnosis is unclear.

Treatment for hydrocele is only indicated when the patient has symptoms since all treatment modalities carries risk of complications, such as hematoma, infection, pain and even infertility concerns has been raised.

Operative management is considered the golden standard of treatment when considering recurrence but less invasive procedures such as sclerotherapy is frequently used, mainly due to cost and complications issues.

Lord´s procedure has in several series shown low frequency of complications and excellent recurrence rates. However, Lord´s procedure and sclerotherapy has not been tested head to head and the optimal treatment for hydrocele is yet to be determined.

This study aims to compare these techniques and evaluate the results within 1 year after randomization on cure, complication rates and various secondary descriptive outcomes.

The investigators aim to adhere to CONSORT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Testicular Hydrocele

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lord´s procedure

Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions

Group Type EXPERIMENTAL

Lord´s procedure

Intervention Type PROCEDURE

Sclerotherapy

Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.

Group Type ACTIVE_COMPARATOR

Sclerotherapy

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lord´s procedure

Intervention Type PROCEDURE

Sclerotherapy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Polidocanol 30mg/ml, 4ml Aetoxysclerol™ 30mg/ml, 4ml Lauromakrogol 400 30mg/ml, 4ml

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic testicular hydrocele, with more than 2 points on a validated inguinal botherscore (Inguinal Pain Questionnaire, IPQ)
* More than 40ml of hydrocele fluid
* Age\>40 years
* Completed reproduction
* Oral and written consent to participate in the study
* American Association of Anesthesiology (ASA) grade≤ 3

Exclusion Criteria

* Other ipsilateral scrotal disease (tumour, ongoing inflammatory disease of the scrotum,)
* Ongoing urinary infection
* Ipsilateral inguinal hernia
* Ascites
* Paternity wish
* Not possible to drain the hydrocele fully
* Opaque fluid drained on emptying the hydrocele
* Bilateral hydrocele where both sides has symptom score more than 2p on IPQ.
Minimum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Umeå University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Karl-Johan Lundström

MD, resident Urologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pär Nordin, Ph.D, MD

Role: STUDY_DIRECTOR

Umeå University

Karl-Johan Lundström, M.D

Role: PRINCIPAL_INVESTIGATOR

Östersunds Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Drammen Hospital

Drammen, , Norway

Site Status RECRUITING

Falu lasarett

Falun, Dalarna County, Sweden

Site Status RECRUITING

Östersunds hospital

Östersund, Jämtland County, Sweden

Site Status RECRUITING

Helsingborgs sjukhus

Helsingborg, Skåne County, Sweden

Site Status RECRUITING

Sundsvalls hospital

Sundsvall, Västernorrland County, Sweden

Site Status RECRUITING

Sunderby Hospital

Luleå, , Sweden

Site Status RECRUITING

Umea University Hospital

Umeå, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Karl-Johan Lundström, M.D

Role: CONTACT

004663153000

Pär Nordin, Ph.D, M.D

Role: CONTACT

004663153000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sven Petter Haugvik, M.D

Role: primary

Carl Gustav Arvidsson, M.D

Role: primary

Nils Edström, M.D

Role: backup

Andreas Forsvall, M.D

Role: primary

Johan Styrke, MD

Role: primary

0046-70-2992048

Ioannis Beis, MD

Role: primary

Jon Fridriksson, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JLL-378961

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.